<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>journal-jmsr</PublisherName>
<JournalTitle>Journal of Medical and Surgical Research</JournalTitle>
<PISSN>I</PISSN>
<EISSN>S</EISSN>
<Volume-Issue>Vol. XII, n 3</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>March 2026</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2026</Year>
<Month>03</Month>
<Day>31</Day>
</PubDate>
<ArticleType>JMSR Oncology</ArticleType>
<ArticleTitle>Molecular Profiling of Colorectal Cancer in a Moroccan Cohort Using Targeted Next-Generation Sequencing</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>1517</FirstPage>
<LastPage>1522</LastPage>
<AuthorList>
<Author>
<FirstName>Soufiane</FirstName>
<LastName>Yassara</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Ismail</FirstName>
<LastName>Boujida</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Youssef</FirstName>
<LastName>Mahdi</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Soumaya</FirstName>
<LastName>Ech-charif</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Chaimae</FirstName>
<LastName>Moujahid</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Fatima-Zahra</FirstName>
<LastName>Bakhtaoui</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Douae</FirstName>
<LastName>Cherqui</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Najlaa</FirstName>
<LastName>Lehmissi</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Chaimaa</FirstName>
<LastName>Mounjid</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Basma El</FirstName>
<LastName>Khannoussi</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Objective: To determine the mutational spectrum and microsatellite instability (MSI) status in colorectal cancer (CRC) patients in Morocco, and to examine associations between the clinical characteristics.Methodology: This prospective study was conducted on 55 patients diagnosed with colorectal adenocarcinoma at the National Institute of Oncology in Rabat. DNA was extracted from FFPE tumor tissues and sequenced using the Oncomine__ampersandsigntrade; Colorectal and Pancreatic Cancer Research Panel. Immunohistochemistry was performed to assess MSI status. Statistical analyses, including correlations between mutations and clinicopathological parameters, were conducted. Results: The study found that APC (45.5%), TP53 (43.6%), KRAS (21.8%), ARID1A (20%), PIK3CA (14.5%) and BRAF (12.7%) were the most common mutations. MSI-high status was found in 9.1% of patients, all of whom were __ampersandsignle;60 years old. Statistical analysis revealed a significant correlation between MSI-high status and age (p = 0.023), with no correlation found between mutations and other clinicopathological parameters. Conclusion: This study provides one of the first comprehensive insight into the mutational landscape of colorectal cancer (CRC) in Morocco, demonstrating a significant associations.The findings highlight the importance of next-generation sequencing (NGS) in guiding personalized treatment strategies for CRC and underscore the need to improve access to molecular diagnostics in Morocco.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Colorectal Cancer, Next-Generation Sequencing, Somatic Mutations, Molecular Diagnostics, Microsatellite Instability, Morocco</Keywords>
<URLs>
<Abstract>https://www.journal-jmsr.net/ubijournal-v1copy/journals/abstract.php?article_id=16205&title=Molecular Profiling of Colorectal Cancer in a Moroccan Cohort Using Targeted Next-Generation Sequencing</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F. and;laquo; Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimate from GLOBOCAN and;raquo;, fand;eacute;vr. 2023, doi: 10.1136/gutjnl-2022-327736.
Registres des cancers, and;laquo; Registres des cancers and;raquo;. Consultand;eacute; le : 28 octobre 2025. [En ligne]. Disponible sur : https://www.contrelecancer.ma/fr/documents/categorie/publications-3/
Xu T, Wang X, Wang Z, Deng T, Qi C, Liu D, Li Y, Ji C, Li J, Shen L. and;laquo; Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors and;raquo;, Ther Adv Med Oncol, vol. 14, p. 17588359221105022, janv. 2022, doi: 10.1177/17588359221105022.
K. He et W.-J. Gan, and;laquo; Wnt/and;beta;-Catenin Signaling Pathway in the Development and Progression of Colorectal Cancer and;raquo;, Cancer Management and Research, vol. 15, no null, p. 435and;#8209;448, dand;eacute;c. 2023, doi: 10.2147/CMAR.S411168.
Y. Tang et Y. Fan, and;laquo; Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis and;raquo;, BMC Cancer, vol. 24, no 1, p. 1155, sept. 2024, doi: 10.1186/s12885-024-12776-8.
I. A. Voutsadakis, and;laquo; From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer and;raquo;, Mol Diagn Ther, sept. 2025, doi: 10.1007/s40291-025-00815-4.
Thermofisher, and;laquo; Invitrogen - MA and;raquo;. Consultand;eacute; le : 11 octobre 2025. [En ligne]. Disponible sur: https://www.thermofisher.com/ng/en/home/brands/invitrogen.html
Gallon R, McCormick L, Saetta A, Albuquerque C, Butler S, Cranston T, Field J, McAnulty C, Silva P, Cheetham M, Sheils K, Burghel GJ. and;laquo; EMQN best practice guidelines for analysis and reporting of microsatellite instability in solid tumours and;raquo;, Eur J Hum Genet, p. 1and;#8209;13, aoand;ucirc;t 2025, doi: 10.1038/s41431-025-01913-x.
Mulet-Margalef N, Linares J, Badia-Ramentol J, Jimeno M, Sanz Monte C, Manzano Mozo JL, Calon A. and;laquo; Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape and;raquo;, Cancers, vol. 15, no 4, p. 1022, janv. 2023, doi: 10.3390/cancers15041022.
Spaander MCW, Zauber AG, Syngal S, Blaser MJ, Sung JJ, You YN, Kuipers EJ. Young and;laquo; Young-onset colorectal cancer and;raquo;, Nat Rev Dis Primers, vol. 9, no 1, p. 21, avr. 2023, doi: 10.1038/s41572-023-00432-7.
E. J. Schafer, H. Sung, J. Star, P. Bandi, R. A. Smith, et R. L. Siegel, and;laquo; Colorectal Cancer Incidence in US Adults After Recommendations for Earlier Screening and;raquo;, JAMA, vol. 334, no 9, p. 824and;#8209;826, sept. 2025, doi: 10.1001/jama.2025.9147.
Y. Ono et O. Yilmaz, and;laquo; Emerging and under-recognised patterns of colorectal carcinoma morphologies: a comprehensive review and;raquo;, Journal of Clinical Pathology, vol. 77, no 7, p. 439and;#8209;451, juill. 2024, doi: 10.1136/jcp-2023-208816.
J. Li, X. Ma, D. Chakravarti, S. Shalapour, et R. A. DePinho, and;laquo; Genetic and biological hallmarks of colorectal cancer and;raquo;, Genes Dev., vol. 35, no 11and;#8209;12, p. 787and;#8209;820, Janv. 2021, doi: 10.1101/gad.348226.120.
Z. Huang et M. Yang, and;laquo; Molecular Network of Colorectal Cancer and Current Therapeutic Options and;raquo;, Front. Oncol., vol. 12, avr. 2022, doi: 10.3389/fonc.2022.852927.
S. A. Bustin et K. A. Jellinger, and;laquo; Advances in Molecular Medicine: Unravelling Disease Complexity and Pioneering Precision Healthcare and;raquo;, International Journal of Molecular Sciences, vol. 24, no 18, p. 14168, Janv. 2023, doi: 10.3390/ijms241814168.
V. M. G. Marbun, L. Erlina, et T. J. M. Lalisang, and;laquo; Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer and;raquo;, PLOS ONE, vol. 17, no 6, p. e0267090, juin 2022, doi: 10.1371/journal.pone.0267090.
Formica V, Sera F, Cremolini C, Riondino S, Morelli C, Arkenau HT, Roselli M, and;laquo; KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis and;raquo;, J Natl Cancer Inst, vol. 114, no 4, p. 517and;#8209;527, avr. 2022, doi: 10.1093/jnci/djab190.
Yassara, S., Mahdi, Y., Khmou, M., Ech-Charif, S., Mounjid, C., Moujahid, C., and; El Khannoussi, B. (2025). Assessment of BRAF Mutations Status in 320 Moroccan Colorectal Cancer Patients and Its Correlation with Clinico-Pathological Characteristics: The Largest North African Case Series. Annals of Cancer Research and Therapy, 33(1), 1and;ndash;4. https://doi.org/10.4993/acrt.33.1
Y. Liu, A. Gusev, Y. J. Heng, L. B. Alexandrov, et P. Kraft, and;laquo; Somatic mutational profiles and germline polygenic risk scores in human cancer and;raquo;, Genome Med, vol. 14, no 1, p. 14, fand;eacute;vr. 2022, doi: 10.1186/s13073-022-01016-y.
Magrin L, Fanale D, Brando C, Fiorino A, Corsini LR, Sciacchitano R, Filorizzo C, Dimino A, Russo A, Bazan V., and;laquo; POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes and;raquo;, Oncogene, vol. 40, no 40, p. 5893and;#8209;5901, oct. 2021, doi: 10.1038/s41388-021-01984-2.
Lahoz S, Rodrand;iacute;guez A, Fernand;aacute;ndez L, Gorrand;iacute;a T, Moreno R, Esposito F, Oliveres H, Albiol S, Saurand;iacute; T, Pesantez D, Riu G, Cuatrecasas M, Jares P, Pedrosa L, Pineda E, Postigo A, Castells A, Prat A, Maurel J, Camps J. and;laquo; Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53and;ndash;Mutated Metastatic Colorectal Cancer and;raquo;, Cancers, vol. 14, no 23, p. 5921, janv. 2022, doi: 10.3390/cancers14235921.</References>
</References>
</Journal>
</Article>
</ArticleSet>